Latest Period
Q4 2025
Security Snapshot
Neurocrine Biosciences Inc - Common Stock Institutional Ownership
CUSIP: 64125C109
13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025
Institutions Reporting
3
Shares (Excl. Options)
2,468,498
Price
$141.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 99,799,872
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 2,468,498
- Total reported value
- $350,107,072
- % of total 13F portfolios
- 0.05%
- Share change
- -766,076
- Value change
- -$108,652,558
- Number of holders
- 3
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- 64125C109 - Neurocrine Biosciences Inc - Common Stock is tracked under CUSIP 64125C109.
- 3 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 1 to 3 between Q3 2024 and Q4 2025.
- Reported value moved from $593,186,319 to $350,107,072.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 3 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 64125C109?
CUSIP 64125C109 identifies 64125C109 - Neurocrine Biosciences Inc - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 64125C109:
Significant Owners of Neurocrine Biosciences Inc - Common Stock based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | 10,129,687 | The Vanguard Group | 28 Feb 2025 | ||||
| STATE STREET CORP | 4.8% | 4,891,137 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Dec 2025, 3 institutional investors reported holding 2,468,498 shares of Neurocrine Biosciences Inc - Common Stock. This represents 2.5% of the company’s total 99,799,872 outstanding shares.
Institutional Holders of Neurocrine Biosciences Inc - Common Stock across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 2,468,498 | $350,107,072 | -$108,652,558 | $141.83 | 3 |
| 2024 Q3 | 5,148,293 | $593,186,319 | +$62,211,426 | $115.22 | 1 |
| 2024 Q2 | 18,799,065 | $2,588,067,279 | +$144,296,607 | $137.67 | 2 |
| 2024 Q1 | 17,750,931 | $2,448,208,404 | +$5,475,976 | $137.92 | 2 |
| 2023 Q4 | 17,711,227 | $2,333,631,267 | $131.76 | 2 |